Diamyd Medical AB
Djurgårdsbrunnsv.54
Stockholm
S-115 25
Tel: 46-8-661-00-26
Website: http://www.diamyd.com/
Email: info@diamyd.com
144 articles about Diamyd Medical AB
-
Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®
2/15/2024
Diamyd Medical announced that the U.S. Food and Drug Administration has granted Fast Track designation for Diamyd® that is being investigated to improve glycemic control in recently diagnosed stage 3 Type 1 Diabetes patients with the genotype HLA DR3-DQ2.
-
Diamyd Medical announces a webcast presentation on October 20 regarding its industry partnership with JDRF
10/17/2023
Diamyd Medical is hosting a webcast presentation on October 20th at 2:00 pm CET / 8:00 am EDT with Ulf Hannelius, CEO of Diamyd Medical, Josh Vieth, Director of Research at JDRF, as well as Mark Atkinson, Director for the University of Florida Diabetes Institute and member of the Board of Directors of Diamyd Medical.
-
Diamyd Medical brings Karin Rosén, M.D, PhD, to its Board of Directors
3/10/2023
Diamyd Medical announced that Karin Rosén, M.D, Ph.D, San Francisco, will join the Board of Directors as an adjunct member, and be proposed for election to the Board at its next General Meeting of Shareholders.
-
US Partial Clinical Hold on Diamyd® Phase III Trial Lifted by the FDA
11/28/2022
Diamyd Medical announced that the U.S. Food and Drug Administration has lifted the partial clinical hold on the confirmatory Phase III trial DIAGNODE-3, evaluating the safety and efficacy of the precision medicine and antigen-specific immunotherapy Diamyd® in individuals recently diagnosed with type 1 diabetes.
-
New meta-analysis with Diamyd® published in scientific journal
4/20/2022
An update of a large-scale meta-analysis supporting the efficacy of the therapeutic diabetes vaccine Diamyd® in individuals recently diagnosed with Type 1 Diabetes carrying the genetic HLA DR3-DQ2 haplotype has been published in the peer-reviewd scientific journal Diabetes, Obesity and Metabolism.
-
Diamyd Medical and partners are awarded SEK 40 million in VINNOVA funding for the prevention of autoimmune diseases
9/23/2021
The Swedish governmental innovation agency VINNOVA provides SEK 40 million in financing for an innovation milieu in sustainable precision health that will be led by Diamyd Medical.
-
Diamyd Medical secures precision medicine patent for prevention and treatment of autoimmune diabetes
8/9/2021
The European Patent Office has informed Diamyd Medical that the Company's patent application regarding prevention and treatment of autoimmune diabetes in individuals carrying the HLA DR3-DQ2 gene will be granted.
-
Update on the design of a Phase III Precision Medicine trial with the Diabetes Vaccine Diamyd®
3/4/2021
The upcoming Phase III trial with Diamyd® in new-onset type 1 diabetes will be based on the first precision medicine approach in the field.
-
Diamyd Medical and Critical Path Institute announce data sharing collaboration to develop advanced drug development tools in type 1 diabetes
12/16/2020
Diamyd Medical and the Critical Path Institute are proud to announce their collaboration to significantly improve the scientific community's insight into type 1 diabetes through Diamyd Medical's contribution of fully anonymized data from a European Phase III trial to the Trial Outcome Measures Initiative T1D integrated database.
-
Diamyd Medical with MainlyAI and KTH awarded VINNOVA funding for AI driven sustainable production
12/3/2020
Diamyd Medical together with MainlyAI AB and KTH Royal Institute of Technology have been awarded funding by the Swedish Governmental Innovation Agency VINNOVA for a project that will design, test and build a sustainability framework powered by artificial intelligence for Diamyd Medical's production facility in Umeå, Sweden.
-
Diamyd Medical invites to a webcast presentation on September 17 on the results from DIAGNODE-2
9/16/2020
Diamyd Medical announced earlier this week that the diabetes vaccine Diamyd® has demonstrated significant effect in a subgroup which covers about half of all type 1 diabetes patients.
-
Diamyd Medical AB (publ) Quarterly Report III 19/20 -September 2019 - May 2020, Fiscal year 2019/2020
6/24/2020
Net result: MSEK 23.2 (-26.8), whereof third quarter MSEK -7.2 (-7.9). The increase compared to previous year is a one-off effect due to a payment of corresponding MSEK 48.0 from the previous GAD65 manufacturer as support for transition of the manufacturing process.
-
Japan Grants Patent for Intralymphatic Administration of the Diabetes Vaccine Diamyd®
4/24/2020
The patent now granted by the Japan Patent Office is valid until 2035. Diamyd Medical recently announced the grant of the corresponding patent in Europe . The patents primarily protect the administration method of Diamyd ® that is now being evaluated in the Phase IIb trial DIAGNODE-2 and which previously showed positive results in t
-
Significant Effect of Diamyd® in Type 1 Diabetes Shown in a New Comprehensive Analysis of Previous Phase III and Phase II Trials
12/12/2019
When treatments with low number and high number dose regimens (two, three and four subcutaneous doses) were combined, a statistically significant treatment effect of approximately 40% was seen.
-
New Interim Report at 30 Months and After Extra Injection Supports Long-term Effect of Intralymphatic Diamyd®
6/4/2019
The first seven patients that have now been followed for the entire 30-month period in DIAGNODE-1 continue to show a positive clinical course and are in partial remission.
-
The Swedish Medical Products Agency Approves New Treatment Arm With Remygen® and Alprazolam in Phase I/II Trial ReGenerate-1
5/29/2019
The approval by the Swedish MPA entails that ReGenerate-1, with Diamyd Medical's GABA-based investigational drug Remygen®, will be expanded from the original two treatment arms encompassing Remygen® administration, with a third treatment arm in which 12 patients receive Remygen® in combination with the GABA receptor modulator Alprazolam.
-
Diamyd Medical Announces Strategic Activities for 2019 and 2020
3/26/2019
With experience from clinical trials in more than 1,000 patients with the diabetes vaccine Diamyd®, preparations for a Conditional Marketing Authorization Application in Europe end of 2020 are underway.
-
Diamyd Medical Raises SEK 58.4 Million in Funds Through Redemption of Warrants
12/6/2018
During 1 to 30 November 2018, holders of warrants of series TO 1 B and TO 2 A of Diamyd Medical AB have been able to subscribe for shares through warrants. A total of 426 037 A shares and 12 409 855 B shares have been subscribed for, which means a subscription rate of 95.6 percent. Diamyd Medical thus raises approximately SEK 58.4 million before issue costs.
-
New Immunological Results That Support Intralymphatic Treatment With Diamyd® to be Presented at the Immunology of Diabetes Society Congress
10/23/2018
New results of intralymphatic treatment with the diabetes vaccine Diamyd® indicate the induction of a long-term immune response that supports the positive clinical results shown in the DIAGNODE-1 trial.
-
Diamyd Medical AB Taps a New CEO
4/11/2016